Urinary biomarkers of bladder cancer: an update and future perspectives
Abbreviated Journal Title
biomarker; bladder cancer; genomics; metabolomics; proteomics; urinary; cytology; urine; TRANSITIONAL-CELL CARCINOMA; IN-SITU HYBRIDIZATION; NUCLEAR-MATRIX; PROTEIN-22; POLYMERASE-CHAIN-REACTION; CARE PROTEOMIC ASSAY; BTA TRAK; ASSAY; UROTHELIAL CARCINOMA; VOIDED-URINE; GENE-EXPRESSION; FOLLOW-UP; Medicine, Research & Experimental
Bladder cancer is one of the most prevalent cancers worldwide. Early detection of bladder tumors is critical for improved patient outcomes. The standard method for detection and surveillance of bladder tumors is cystoscopy with urinary cytology. Limitations of cystoscopy and urinary cytology have brought to light the need for more robust diagnostic assays. Ideally, such assays would be applicable to noninvasively obtained, voided urine, and be designed not only for diagnosis, but also for monitoring disease recurrence and response to therapy. Consequently, the development of a noninvasive urine-based assay would be of tremendous benefit to both patients and healthcare systems. This article reports some of the more prominent urine-based biomarkers reported in the literature. In addition, some new technologies that have been used to identify novel urinary biomarkers are highlighted.
Biomarkers in Medicine
"Urinary biomarkers of bladder cancer: an update and future perspectives" (2013). Faculty Bibliography 2010s. 4618.